-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Efavirenz-[d5]
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1132642-95-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1132642-95-5 |
| Description | Efavirenz-[d5] is the labelled analogue of Efavirenz. Efavirenz is an antiretroviral medication used to treat and prevent HIV/AIDS. |
Product Information
| Synonyms | Efavirenz D5; Sustiva-d5; Stocrin-d5; DMP-266-d5; EFV-d5; (4S)-6-Chloro-4-(Cyclopropylethynyl)-1,4-Dihydro-4-(Trifluoromethyl)-2H-3,1-Benzoxazin-2-One-d5 |
| IUPAC Name | (4S)-6-chloro-4-[2-(1,2,2,3,3-pentadeuteriocyclopropyl)ethynyl]-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one |
| Molecular Weight | 320.71 |
| Molecular Formula | C14H4D5ClF3NO2 |
| Canonical SMILES | C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F |
| InChI | InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1/i1D2,2D2,8D |
| InChIKey | XPOQHMRABVBWPR-XWJABCKYSA-N |
| Boiling Point | 340.6±42.0°C at 760 mmHg |
| Melting Point | 182-185°C |
| Purity | >98% |
| Density | 1.5±0.1 g/cm3 |
| Solubility | Soluble in Chloroform, DMSO, Methanol |
| Appearance | Off-white to Pale Beige Solid |
| Storage | Store at -20°C |
| Complexity | 519 |
| Exact Mass | 320.0587744 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| PSA | 41.82000 |
| Target | Reverse Transcriptase; HIV; Autophagy |
| XLogP3-AA | 4 |
